Compare Stocks: GNFT, ANL, MLTX, and KURA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANL Adlai Nortye	$15.62	$14.57	$0.88 ▼ $17.25	$1.01B	1.05	188,807 shs	300,393 shs
GNFT GENFIT	$4.85	$4.47	$3.41 ▼ $4.93	$242.62M	1.09	7,393 shs	N/A
KURA Kura Oncology	$10.60	$11.36	$7.36 ▼ $13.90	$942.99M	0.47	1.77 million shs	1.47 million shs
MLTX MoonLake Immunotherapeutics	$10.82	$14.27	$8.80 ▼ $23.29	$920.89M	1.08	2.04 million shs	2.01 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANL Adlai Nortye	0.00%	+3.51%	+2.70%	+69.05%	+846.67%
GNFT GENFIT	0.00%	0.00%	0.00%	0.00%	+14.93%
KURA Kura Oncology	0.00%	-0.47%	-6.94%	-2.84%	+7.61%
MLTX MoonLake Immunotherapeutics	0.00%	-5.17%	-13.51%	-46.99%	+5.46%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANL Adlai Nortye	$15.62	$14.57	$0.88 ▼ $17.25	$1.01B	1.05	188,807 shs	300,393 shs
GNFT GENFIT	$4.85	$4.47	$3.41 ▼ $4.93	$242.62M	1.09	7,393 shs	N/A
KURA Kura Oncology	$10.60	$11.36	$7.36 ▼ $13.90	$942.99M	0.47	1.77 million shs	1.47 million shs
MLTX MoonLake Immunotherapeutics	$10.82	$14.27	$8.80 ▼ $23.29	$920.89M	1.08	2.04 million shs	2.01 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANL Adlai Nortye	0.00%	+3.51%	+2.70%	+69.05%	+846.67%
GNFT GENFIT	0.00%	0.00%	0.00%	0.00%	+14.93%
KURA Kura Oncology	0.00%	-0.47%	-6.94%	-2.84%	+7.61%
MLTX MoonLake Immunotherapeutics	0.00%	-5.17%	-13.51%	-46.99%	+5.46%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANL Adlai Nortye	2.86	Moderate Buy	$29.50	88.86% Upside
GNFT GENFIT	1.00	Sell	N/A	N/A
KURA Kura Oncology	2.77	Moderate Buy	$25.69	142.33% Upside
MLTX MoonLake Immunotherapeutics	2.43	Hold	$28.50	163.40% Upside

Current Analyst Ratings Breakdown

Latest GNFT, ANL, MLTX, and KURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/5/2026	KURA Kura Oncology	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
10/5/2026	ANL Adlai Nortye	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
10/5/2026	MLTX MoonLake Immunotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
10/1/2026	KURA Kura Oncology	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$30.00
9/16/2026	MLTX MoonLake Immunotherapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/10/2026	ANL Adlai Nortye	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$31.00
9/8/2026	ANL Adlai Nortye	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$49.00
9/8/2026	ANL Adlai Nortye	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
8/24/2026	KURA Kura Oncology	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$24.00
8/24/2026	KURA Kura Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$24.00
8/24/2026	KURA Kura Oncology	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform

(Data available from 10/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANL Adlai Nortye	$18.06M	55.71	N/A	N/A	($0.21) per share	-74.38
GNFT GENFIT	$41.52M	5.84	$0.07 per share	69.34	$1.50 per share	3.23
KURA Kura Oncology	$77.23M	12.21	N/A	N/A	$2.00 per share	5.30
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$4.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANL Adlai Nortye	-$35.53M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GNFT GENFIT	$1.63M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	-$278.67M	-$3.37	N/A	N/A	N/A	-384.30%	-207.18%	-45.17%	11/3/2026 (Estimated)
MLTX MoonLake Immunotherapeutics	-$227.32M	-$3.84	N/A	N/A	N/A	N/A	-82.53%	-58.17%	11/4/2026 (Estimated)

Latest GNFT, ANL, MLTX, and KURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	MLTX MoonLake Immunotherapeutics	-$0.77	N/A	N/A	N/A	N/A	N/A
11/3/2026	Q3 2026	KURA Kura Oncology	-$0.8144	N/A	N/A	N/A	$23.81 million	N/A
8/12/2026	Q2 2026	KURA Kura Oncology	-$0.8773	-$0.77	+$0.1073	-$0.77	$20.16 million	$20.87 million
8/10/2026	Q2 2026	MLTX MoonLake Immunotherapeutics	-$0.9086	-$0.84	+$0.0686	-$0.84	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANL Adlai Nortye	N/A	N/A	N/A	N/A	N/A
GNFT GENFIT	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANL Adlai Nortye	0.04	9.55	N/A
GNFT GENFIT	0.09	3.74	3.74
KURA Kura Oncology	0.12	4.73	4.71
MLTX MoonLake Immunotherapeutics	0.23	12.56	12.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANL Adlai Nortye	35.21%
GNFT GENFIT	2.24%
KURA Kura Oncology	N/A
MLTX MoonLake Immunotherapeutics	93.85%

Insider Ownership

Company	Insider Ownership
ANL Adlai Nortye	N/A
GNFT GENFIT	4.20%
KURA Kura Oncology	7.60%
MLTX MoonLake Immunotherapeutics	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANL Adlai Nortye	109	64.40 million	N/A	Not Optionable
GNFT GENFIT	120	50.03 million	47.92 million	Not Optionable
KURA Kura Oncology	260	88.96 million	82.20 million	Optionable
MLTX MoonLake Immunotherapeutics	130	85.11 million	76.26 million	Optionable

GNFT, ANL, MLTX, and KURA Headlines

Recent News About These Companies

MoonLake Immunotherapeutics (MLTX) Receives a Rating Update from a Top Analyst

October 8, 2026 | theglobeandmail.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given "Buy" Rating at HC Wainwright

October 5, 2026 | americanbankingnews.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Buy Rating at HC Wainwright

October 5, 2026 | marketbeat.com

MoonLake Immunotherapeutics Files Biologics License Application for Sonelokimab to Treat Hidradenitis Suppurativa

October 2, 2026 | kalkinemedia.comK

Analysts’ Opinions Are Mixed on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX) and Liquidia Technologies (LQDA)

October 2, 2026 | theglobeandmail.com

MoonLake files FDA application for sonelokimab therapy

September 30, 2026 | tipranks.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Rated "Moderate Buy" by Sell-Side Analysts

September 29, 2026 | marketbeat.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Bumped Down to Strong Sell by Wall Street Zen

September 27, 2026 | marketbeat.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Raised to Sell at Wall Street Zen

September 19, 2026 | marketbeat.com

111,590 Shares in MoonLake Immunotherapeutics $MLTX Purchased by Engineers Gate Manager LP

September 15, 2026 | marketbeat.com

MLTX stock on track for worst week since last fall as FDA filing date for skin disease drug draws near

September 11, 2026 | msn.com

MoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical Supremacy

September 8, 2026 | seekingalpha.com

MoonLake Immunotherapeutics (MLTX)

August 23, 2026 | finance.yahoo.com

MoonLake’s psoriatic arthritis drug shows promise in phase 3 trial – retail shrugs off premarket slide, says ‘pipeline is intact’

August 11, 2026 | msn.com

MoonLake Immunotherapeutics Q2 Loss Narrows, Phase 3 PsA Trial Meets Clinical Goals

August 10, 2026 | finance.yahoo.com

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical ...

August 10, 2026 | markets.businessinsider.com

MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study

August 10, 2026 | benzinga.com

MoonLake's psoriatic arthritis drug meets key goals in late-stage trial

August 10, 2026 | reuters.com

MoonLake announces positive Phase 3 psoriatic arthritis results

August 10, 2026 | tipranks.com

MoonLake reports positive Phase 3 PsA data and $537 million cash

August 10, 2026 | quiverquant.comQ

MoonLake Immunotherapeutics GAAP EPS of -$0.84

August 10, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GNFT, ANL, MLTX, and KURA Company Descriptions

Adlai Nortye NASDAQ:ANL

$15.62 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$15.83 +0.21 (+1.36%)

As of 06:28 AM Eastern

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

GENFIT NASDAQ:GNFT

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Kura Oncology NASDAQ:KURA

$10.60 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$10.74 +0.14 (+1.29%)

As of 06:50 AM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

MoonLake Immunotherapeutics NASDAQ:MLTX

$10.82 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$10.86 +0.04 (+0.33%)

As of 06:45 AM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GNFT, ANL, MLTX, and KURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GNFT, ANL, MLTX, and KURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GNFT, ANL, MLTX, and KURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GNFT, ANL, MLTX, and KURA Company Descriptions

Adlai Nortye NASDAQ:ANL

GENFIT NASDAQ:GNFT

Kura Oncology NASDAQ:KURA

MoonLake Immunotherapeutics NASDAQ:MLTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GNFT, ANL, MLTX, and KURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GNFT, ANL, MLTX, and KURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GNFT, ANL, MLTX, and KURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GNFT, ANL, MLTX, and KURA Company Descriptions

Adlai Nortye NASDAQ:ANL

GENFIT NASDAQ:GNFT

Kura Oncology NASDAQ:KURA

MoonLake Immunotherapeutics NASDAQ:MLTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools